Entries by Maren Kühr

Fermentation fuels ingredient innovation

Biotech innovator Biosyntia ApS, the latest addition to the ECBF, is applying proprietary biological processes to produce sustainable nutritional ingredients – a mission that has captured the imagination of seasoned biotech investors and major ingredient players.

Ingenza appoints Steve Jones as new CFO

Steve Jones took over the role of Chief Financial Officer (CFO) at the biotech company Ingenza Ltd (UK) at the beginning of April. He brings many years of experience and expertise in finance, having held a variety of senior positions.

From lab to industrial scale bioreactors

Sweden’s Belach Bioteknik has been partnering mostly with researchers and pharma customers to design suited bioreactor systems for biomanufacturing. Most recently, the company has entered the growing cultured meat sector, in which many companies are currently scaling up their production and thus need expertise to get optimal results.

Biotech funding environment calls for more creativity

From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder to come by these days. The answer can only be more creativity in structuring deals.

Biopharma partnership intensifying purification

DSP?Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides ­selected insights on Catalent’s findings from the collaboration.

Biopharma partnership – intensifying purification

DSP Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides ­selected insights on Catalent’s findings from the collaboration.

Biomanufacturing: Step up and speak up

In a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday life. It needs higher visibility and recognition of impact, moving beyond its ‘enabling’ brand which forever makes it sound like the benefits are just around the corner, rather than the existing significant economic and industrial impact.